Janney Montgomery Scott LLC Buys 732 Shares of Stryker Corporation (NYSE:SYK)

Janney Montgomery Scott LLC lifted its stake in Stryker Corporation (NYSE:SYK - Free Report) by 1.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 69,157 shares of the medical technology company's stock after acquiring an additional 732 shares during the quarter. Janney Montgomery Scott LLC's holdings in Stryker were worth $25,744,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Stryker by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock valued at $11,773,213,000 after buying an additional 252,188 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Stryker by 0.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company's stock worth $4,000,056,000 after acquiring an additional 54,693 shares during the period. FMR LLC increased its position in Stryker by 10.0% during the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock valued at $2,892,946,000 after acquiring an additional 727,850 shares during the last quarter. Geode Capital Management LLC increased its position in Stryker by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock valued at $2,539,033,000 after acquiring an additional 168,436 shares during the last quarter. Finally, Norges Bank bought a new position in Stryker in the fourth quarter valued at about $1,710,744,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Performance

NYSE SYK opened at $373.36 on Wednesday. The company has a quick ratio of 1.00, a current ratio of 1.64 and a debt-to-equity ratio of 0.69. Stryker Corporation has a twelve month low of $314.93 and a twelve month high of $406.19. The business has a 50-day moving average price of $373.73 and a 200-day moving average price of $375.54. The firm has a market cap of $142.51 billion, a price-to-earnings ratio of 50.45, a price-to-earnings-growth ratio of 2.84 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.11. The business had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.50 EPS. As a group, equities research analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be given a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.90%. Stryker's payout ratio is 45.41%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on SYK shares. Needham & Company LLC restated a "buy" rating and set a $442.00 price target on shares of Stryker in a research note on Friday, March 21st. Citigroup restated a "buy" rating and set a $455.00 target price (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. BTIG Research set a $403.00 target price on shares of Stryker and gave the company a "buy" rating in a report on Monday, April 14th. Sanford C. Bernstein set a $450.00 price target on shares of Stryker in a research note on Monday, May 5th. Finally, Evercore ISI cut their price objective on shares of Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $427.30.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the transaction, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 5.20% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.